Literature DB >> 17505110

Crystal structure of CD59: implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attack complex.

Yuxiang Huang1, Alena Fedarovich, Stephen Tomlinson, Christopher Davies.   

Abstract

Human CD59 is a small membrane-bound glycoprotein that functions as an inhibitor of the membrane-attack complex (MAC) of the complement system by binding the complement proteins C8 and C9. The crystal structure of a soluble construct of CD59 has been determined to 2.1 A resolution. When compared with previous models of CD59 determined using NMR, some interesting differences are noted, including the position of helix alpha1, which contributes to the binding surface for C8 and C9. Interestingly, the crystal structure superimposes more closely with an updated NMR model of CD59 that was produced using Monte Carlo minimization, including helix alpha1. Mapping of mutations associated with enhanced or lowered inhibitory function of CD59 show the binding region to be located in a crevice between alpha1 and a three-stranded beta-sheet, as has been identified previously. Residues in the core of this region are well ordered in the electron density, in part owing to a network of stabilizing covalent and noncovalent interactions, and manifest an interesting 'striped' distribution of hydrophobic and basic residues. Docking of the same peptide that was modeled previously into the NMR structure shows that Arg55, which has been postulated to exist in 'open' and 'closed' positions, is intermediate in position between these two and is well placed to contact the peptide. Further clues regarding how CD59 interacts with small peptides arise from the crystal packing of this structure, which shows that a symmetry-related loop comprising residues 20-24 occupies a spatially similar position to the modeled peptide. This higher resolution structure of CD59 will facilitate a more precise dissection of its interactions with C8 and C9 and thus increase the likelihood of designing enhanced CD59-based therapeutics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17505110     DOI: 10.1107/S0907444907015557

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  19 in total

1.  Removal of the tag from His-tagged ILYd4, a human CD59 inhibitor, significantly improves its physical properties and its activity.

Authors:  Lin Wu; Sanbao Su; Fengming Liu; Tao Xu; Xiaoxiao Wang; Yan Huang; Xinlu Sun; Xiaowen Ge; Ting Chen; Huixia Liu; Chun Wang; Michael Chorev; Ting Xu; Xuebin Qin
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 2.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

3.  Transient GPI-anchored protein homodimers are units for raft organization and function.

Authors:  Kenichi G N Suzuki; Rinshi S Kasai; Koichiro M Hirosawa; Yuri L Nemoto; Munenori Ishibashi; Yoshihiro Miwa; Takahiro K Fujiwara; Akihiro Kusumi
Journal:  Nat Chem Biol       Date:  2012-07-22       Impact factor: 15.040

4.  A new blood group antigen is defined by anti-CD59, detected in a CD59-deficient patient.

Authors:  Markus Anliker; Inge von Zabern; Britta Höchsmann; Henriette Kyrieleis; Christian Dohna-Schwake; Willy A Flegel; Hubert Schrezenmeier; Christof Weinstock
Journal:  Transfusion       Date:  2014-01-03       Impact factor: 3.157

5.  Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia.

Authors:  Gunilla Olivecrona; Ewa Ehrenborg; Henrik Semb; Elena Makoveichuk; Anna Lindberg; Michael R Hayden; Peter Gin; Brandon S J Davies; Michael M Weinstein; Loren G Fong; Anne P Beigneux; Stephen G Young; Thomas Olivecrona; Olle Hernell
Journal:  J Lipid Res       Date:  2009-12-21       Impact factor: 5.922

6.  Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells.

Authors:  Tao You; Weiguo Hu; Xiaowen Ge; Jingnan Shen; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2011-01-24       Impact factor: 11.530

Review 7.  GPIHBP1, an endothelial cell transporter for lipoprotein lipase.

Authors:  Stephen G Young; Brandon S J Davies; Constance V Voss; Peter Gin; Michael M Weinstein; Peter Tontonoz; Karen Reue; André Bensadoun; Loren G Fong; Anne P Beigneux
Journal:  J Lipid Res       Date:  2011-08-15       Impact factor: 5.922

8.  GPIHBP1 and the processing of triglyceride-rich lipoproteins.

Authors:  Anne P Beigneux
Journal:  Clin Lipidol       Date:  2010-08-01

9.  Chylomicronemia with low postheparin lipoprotein lipase levels in the setting of GPIHBP1 defects.

Authors:  Remco Franssen; Stephen G Young; Frank Peelman; Jozef Hertecant; Jeroen A Sierts; Alinda W M Schimmel; André Bensadoun; John J P Kastelein; Loren G Fong; Geesje M Dallinga-Thie; Anne P Beigneux
Journal:  Circ Cardiovasc Genet       Date:  2010-02-02

10.  Highly conserved cysteines within the Ly6 domain of GPIHBP1 are crucial for the binding of lipoprotein lipase.

Authors:  Anne P Beigneux; Peter Gin; Brandon S J Davies; Michael M Weinstein; André Bensadoun; Loren G Fong; Stephen G Young
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.